Stockreport

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2024

Immunovant, Inc.  (IMVT) 
PDF Completed enrollment in batoclimab pivotal Myasthenia Gravis (MG) trial; top-line results and initiation of a potentially registrational program for IMVT-1402 on track f [Read more]